Author: "Martine Neau" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Martine Neau"' showing total 57 results

Start Over Author "Martine Neau"

57 results on '"Martine Neau"'

1. TOP-005 Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management

Author: De Martin, Eleonora, primary, Antonini, Teresa, additional, Ningarhari, Massih, additional, Hilleret, Marie-Noëlle, additional, Allaire, Manon, additional, Del Bello, Arnaud, additional, Amaddeo, Giuliana, additional, Besch, Camille, additional, Cransac, Martine Neau, additional, Jaillais, Anais, additional, Ollivier-Hourmand, Isabelle, additional, Dharancy, Sébastien, additional, Decaens, Thomas, additional, Conti, Filomena, additional, Saliba, Faouzi, additional, Rosmorduc, Olivier, additional, Dumortier, Jérôme, additional, and Coilly, Audrey, additional
Published: 2024
Full Text: View/download PDF

2. Long‐term outcome of liver transplantation for autoimmune hepatitis: A French nationwide study over 30 years

Author: Yasmina Chouik, Olivier Chazouillères, Claire Francoz, Eleonora De Martin, Olivier Guillaud, Armand Abergel, Mario Altieri, Louise Barbier, Camille Besch, Filomena Conti, Christophe Corpechot, Sébastien Dharancy, François Durand, Christophe Duvoux, Jean Gugenheim, Jean Hardwigsen, Marie‐Noëlle Hilleret, Pauline Houssel‐Debry, Nassim Kamar, Delphine Maucort‐Boulch, Anne Minello, Martine Neau‐Cransac, Georges‐Philippe Pageaux, Sylvie Radenne, Olivier Roux, Faouzi Saliba, Olivier Serée, Didier Samuel, Claire Vanlemmens, Marie‐Lorraine Woehl‐Jaegle, Vincent Leroy, Jean‐Charles Duclos‐Vallée, and Jérôme Dumortier
Subjects: Hepatology
Published: 2023
Full Text: View/download PDF

3. Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome

Author: Yasmina Chouik, Claire Francoz, Eleonora De Martin, Olivier Guillaud, Armand Abergel, Mario Altieri, Louise Barbier, Camille Besch, Olivier Chazouillères, Filomena Conti, Christophe Corpechot, Sébastien Dharancy, François Durand, Christophe Duvoux, Jean Gugenheim, Jean Hardwigsen, Marie‐Noëlle Hilleret, Pauline Houssel‐Debry, Nassim Kamar, Anne Minello, Martine Neau‐Cransac, Georges‐Philippe Pageaux, Sylvie Radenne, Olivier Roux, Faouzi Saliba, Didier Samuel, Claire Vanlemmens, Marie‐Lorraine Woehl‐Jaegle, Vincent Leroy, Jean‐Charles Duclos‐Vallée, Jérôme Dumortier, Hospices Civils de Lyon (HCL), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Edouard Herriot [CHU - HCL], Clinique de la Sauvegarde [Lyon], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Hôpital de Hautepierre [Strasbourg], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Henri Mondor [Créteil], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), and Fondation Léon Bouchut
Subjects: early infection, MESH: Liver Transplantation, immunosuppression, MESH: Humans, Hepatology, MESH: Hepatitis, Autoimmune, fulminant hepatitis, MESH: Adult, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, survival, sepsis, MESH: Massive Hepatic Necrosis, MESH: Female, MESH: Sepsis
Abstract: Background and aims: Autoimmune hepatitis (AIH) is a rare indication (
Published: 2023
Full Text: View/download PDF

4. COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders

Author: Hannah, Kaminski, Mickael, Gigan, Agathe, Vermorel, Manon, Charrier, Laura, Guirle, Frederic, Jambon, Arthur, Lacapère, Coline, Ménard, Karine, Moreau, Martine, Neau-Cransac, Marine, Novion, Frederique, Pribat, Benjamin, Taton, Sébastien, Borde, Laure, Burguet, Charlie, Martinez, Magali, Jasiek, Pauline, D'Halluin, Marie-Edith, Lafon, Pierre, Merville, and Lionel, Couzi
Subjects: Vaccines, Nephrology, Antibodies, Monoclonal, COVID-19, Humans, Pre-Exposure Prophylaxis, Morbidity, Kidney Transplantation
Published: 2022
Full Text: View/download PDF

5. Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study

Author: Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, Jean Gugenheim, Nassim Kamar, Ephrem Salamé, Martine Neau‐Cransac, Claire Vanlemmens, François Durand, Georges‐Philippe Pageaux, Jean Hardwigsen, Yasmina Benkhatar, François Derquenne, and Filomena Conti
Subjects: Graft Rejection, Carcinoma, Hepatocellular, Hepatology, Calcineurin Inhibitors, Graft Survival, Liver Neoplasms, Humans, Everolimus, Immunosuppressive Agents, Tacrolimus, Liver Transplantation
Abstract: To report 5-year outcomes of the CERTITUDE study.An observational study in patients with liver transplantation (LTx) compared the long-term impact of immunosuppression (with/without a calcineurin inhibitor) on renal function, cancers, major cardiovascular events (MACEs) and other safety parameters. All patients completing the 6-month SIMCER study were recruited and analysed according to treatment received at randomization and actual treatment received during the follow-up.Of the 143 enrolled patients, 119 completed the 5-year follow-up (everolimus [EVR], n = 55; tacrolimus [TAC], n = 64). The mean absolute change in estimated glomerular filtration rate was not statistically different between both groups (TAC, -15.53 ml/min/1.73 mThe CERTITUDE study demonstrated that EVR- and TAC-based regimens have comparable efficacy, safety and tolerability up to 5 years post-LTx.
Published: 2022

6. Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies

Author: Olivier Boillot, Nicolas Congy-Jolivet, Laurence Lavayssière, Marie Danjoux, Jérôme Dumortier, Arnaud Del Bello, Jonathan Visentin, Valérie Dubois, Brigitte Le Bail, Martine Neau-Cransac, Valérie Hervieu, Teresa Antonini, and Nassim Kamar
Subjects: Graft Rejection, METAVIR Fibrosis Score, medicine.medical_specialty, medicine.medical_treatment, 030230 surgery, Liver transplantation, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, HLA Antigens, Internal medicine, medicine, Risk of mortality, Humans, Retrospective Studies, Transplantation, Hepatology, medicine.diagnostic_test, business.industry, Graft Survival, Hazard ratio, Retrospective cohort study, Tissue Donors, Liver Transplantation, Liver biopsy, 030211 gastroenterology & hepatology, Surgery, Rituximab, business, medicine.drug
Abstract: After liver transplantation (LT), the role of preformed donor-specific anti-human leukocyte antigen antibodies (pDSAs) remains incompletely understood. We conducted a retrospective, case-control analysis to determine the impact of pDSAs after LT in 3 French transplant centers (Bordeaux, Lyon, and Toulouse). Among the 1788 LTs performed during the study period, 142 (7.9%) had at least 1 pDSA. The patient survival rate was not different between patients who received an LT with pDSAs and the matched-control group. A liver biopsy was performed 1 year after transplantation in 87 recipients. The metavir fibrosis score did not differ between both groups (1 ± 0.8 versus 0 ± 0.8; P = 0.80). However, undergoing a retransplantation (hazard ratio [HR] = 2.6, 95% confidence interval [CI], 1.02-6.77; P = 0.05) and receiving induction therapy with polyclonal antibodies (HR = 2.5; 95% CI, 1.33-4.74; P = 0.01) were associated with a higher risk of mortality. Nonetheless, high mean fluorescence intensity (MFI) donor-specific antibodies (ie, >10,000 with One Lambda assay or >5000 with Immucor assay) were associated with an increased risk of acute rejection (HR = 2.0; 95% CI, 1.12-3.49; P = 0.02). Acute antibody-mediated rejection was diagnosed in 10 patients: 8 recipients were alive 34 (1-125) months after rejection. The use of polyclonal antibodies or rituximab as an induction therapy did not reduce the risk of acute rejection, but it increased the risk of infectious complications. In conclusion, high MFI pDSAs increase the risk of graft rejection after LT, but they do not reduce medium-term and longterm patient survival. The use of a T or B cell-depleting agent did not reduce the risk of acute rejection.
Published: 2019
Full Text: View/download PDF

7. Long term results of liver transplantation for alpha-1 antitrypsin deficiency

Author: Alain Lachaux, Eduardo Couchonnal, Christophe Duvoux, Jean Gugenheim, Dominique Debray, Sylvie Radenne, Marie-Noëlle Hilleret, Emmanuel Jacquemin, Filomena Conti, Audrey Coilly, Claire Vanlemmens, Olivier Guillaud, Florence Lacaille, Yasmina Chouik, Valérie A. McLin, Didier Samuel, Nassim Kamar, Georges-Philippe Pageaux, Emmanuel Gonzales, Oanez Ackermann, Jean-Charles Duclos-Vallée, Claire Francoz, Jérôme Dumortier, Mathias Ruiz, Pauline Houssel-Debry, Martine Neau-Cransac, Herrada, Anthony, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Clinique de la Sauvegarde [Lyon], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Grenoble, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pontchaillou [Rennes], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nice (CHU Nice), Université de Lyon, Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpitaux Universitaires de Genève (HUG), Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, CHU Toulouse [Toulouse], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de Rangueil, and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, Survival, medicine.medical_treatment, Kaplan-Meier Estimate, Liver transplantation, Gastroenterology, Disease-Free Survival, 03 medical and health sciences, Liver disease, 0302 clinical medicine, alpha 1-Antitrypsin Deficiency, Internal medicine, Genotype, medicine, Humans, Child, Alpha1 antitrypsin, Outcome, Alpha 1-antitrypsin deficiency, ddc:618, Hepatology, business.industry, Medical record, Graft Survival, Retrospective cohort study, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Middle Aged, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, 030220 oncology & carcinogenesis, Cohort, Population study, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies
Abstract: International audience; Introduction: Liver transplantation (LT) is the therapeutic option for end-stage liver disease associated with alpha1 antitrypsin (A1AT) deficiency. The aim of the present retrospective study was to report on long-term outcomes following LT for A1AT deficiency.Methods: The medical records of 90 pediatric and adult patients transplanted between 1982 and 2017 in France and Geneva (Switzerland) were reviewed.Results: The study population consisted of 32 adults and 58 children; median age at transplant was 13.0 years (range: 0.2-65.1), and 65 were male (72.2%). Eighty-two patients (94.8% of children and 84.4% of adults) had the PI*ZZ genotype/phenotype and eight patients (8.9%) had the Pi*SZ genotype/phenotype. Eighty-four patients (93.3%) were transplanted for end-stage liver disease and six (all Pi*ZZ adults) for HCC. Median follow-up after LT was 13.6 years (0.1-31.7). The overall cumulative patient survival rates post-transplant were 97.8% at 1 year, and 95.5%, 95.5%, 92.0%, 89.1% at 5, 10, 15, 20 years respectively. The overall cumulative graft survival rates were 92.2% at 1 year, and 89.9%, 89.9%, 84.4%, 81.5% at 5, 10, 15 and 20 years, respectively.Conclusions: In a representative cohort of patients having presented with end-stage-liver disease or HCC secondary to A1AT, liver transplantation offered very good patient and graft survival rates.
Published: 2021
Full Text: View/download PDF

8. Overcoming non-specific binding to measure the active concentration and kinetics of serum anti-HLA antibodies by surface plasmon resonance

Author: Jean-Luc Taupin, Claire Dromer, Jonathan Visentin, Pierre Merville, Martine Neau-Cransac, Vincent Veniard, Carmelo Di Primo, Gwendaline Guidicelli, Karine Nubret-le Coniat, and Lionel Couzi
Subjects: 0301 basic medicine, Kinetics, Biomedical Engineering, Biophysics, Biosensing Techniques, Human leukocyte antigen, Antibodies, 03 medical and health sciences, Limit of Detection, Electrochemistry, Humans, Surface plasmon resonance, Oligonucleotide Array Sequence Analysis, Detection limit, biology, Chemistry, Histocompatibility Antigens Class I, General Medicine, Surface Plasmon Resonance, Fluorescence, Receptor–ligand kinetics, 030104 developmental biology, biology.protein, Antibody, Biosensor, Biotechnology
Abstract: Human leukocyte antigen (HLA) donor-specific antibodies are key serum biomarkers for assessing the outcome of transplanted patients. Measuring their active concentration, i.e. the fraction that really interacts with donor HLA, and their affinity could help deciphering their pathogenicity. Surface plasmon resonance (SPR) is recognized as the gold-standard for measuring binding kinetics but also active concentrations, without calibration curves. SPR-based biosensors often suffer from non-specific binding (NSB) occurring with the sensor chip surface and the immobilized targets, especially for complex media such as human serum. In this work we show that several serum treatments such as dialysis or IgG purification reduce NSB but insufficiently for SPR applications. We then demonstrate that the NSB contribution to the SPR signal can be eliminated to determine precisely and reliably the active concentration and the affinity of anti-HLA antibodies from patients' sera. This was achieved even at concentrations close to the limit of quantification of the method, in the 0.5–1 nM range. The robustness of the assay was demonstrated by using a wide range of artificially generated NSB and by varying the density of the targets captured onto the surface. The assay is of general interest and can be used with molecules generating strong NSB, as far as a non-cognate target structurally close to the target can be captured on the same flow cell, in a different binding cycle. Compared with current fluorescence-based methods that are semi-quantitative, we expect this SPR-based assay to help better understanding anti-HLA antibodies pathogenicity and improving organ recipients’ management.
Published: 2018
Full Text: View/download PDF

9. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients

Author: Christophe Duvoux, Mario Altieri, Nassim Kamar, Jean Gugenheim, Sébastien Dharancy, Filomena Conti, Armand Abergel, Olivier Sérée, Georges-Philippe Pageaux, Ephrem Salamé, Jean Hardwigsen, Karim Boudjema, Pascal Lebray, Philippe Segol, Camille Besch, Vincent Leroy, Didier Samuel, Guy Launoy, Claire Vanlemmens, Sylvie Radenne, Maryline Debette-Gratien, Olivier Chazouillères, Xavier Blaizot, Martine Neau-Cransac, Claire Francoz, Marianne Latournerie, Jérôme Dumortier, Audrey Coilly, Pauline Houssel-Debry, François Durand, Olivier Boillot, Faouzi Saliba, Thierry Lobbedez, CCSD, Accord Elsevier, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, CHU Pontchaillou [Rennes], Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Centre de Référence des Maladies Rares - Maladies Inflammatoires des Voies Biliaires et Service d’Hépatologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Henri Mondor, Ecole Polytechnice Universitaire de Nice (EPU Nice -Polytech'Nice-Sophia), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Néphrologie - Immunologie Clinique [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-PRES Université de Toulouse, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hospices Civils de Lyon (HCL), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and CHU Strasbourg
Subjects: Oncology, Adult, Male, medicine.medical_specialty, MESH: Liver Transplantation, Liver tumor, medicine.medical_treatment, Liver transplantation, Malignancy, Primary sclerosing cholangitis, 03 medical and health sciences, Liver disease, 0302 clinical medicine, MESH: Liver Neoplasms, MESH: Risk Factors, Risk Factors, Internal medicine, medicine, Humans, MESH: Incidence, Lung cancer, Retrospective Studies, MESH: Humans, Hepatology, business.industry, Incidence, Liver Neoplasms, Gastroenterology, Retrospective cohort study, MESH: Adult, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Competing risk, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Male, Liver Transplantation, 030220 oncology & carcinogenesis, Population study, 030211 gastroenterology & hepatology, business, Liver transplantationde novomalignancies
Abstract: International audience; Background: After liver transplantation (LT),de novo malignancies are one of the leading causes of late mortality. The aim of the present retrospective study was to identify the risk factors of de novo malignancies in a large cohort of LT recipients in France, using Fine and Gray competing risks regression analysis.Methods: The study population consisted in 11004 adults transplanted between 2000 and 2013, who had no history of pre-transplant malignancy, except primary liver tumor. A Cox model adapted to the identification of prognostic factors (competitive risks) was used.Results: From the entire cohort, one (or more)de novo malignancy was reported in 1480 L T recipients (13.45%). The probability to develop a de novo malignancy after LT was 2.07% at 1 year, 13.30% at 5 years, and 28.01% at 10 years. Of the known reported malignancies, the most common malignancies were hematological malignancy (22.36%), non-melanoma skin cancer (19.53%) and lung cancer (12.36%). According to Fine and Gray competing risks regression multivariate analysis, were significant risk factors for post-LT de novo malignancy: recipient age (Subdistribution Hazard Ratio (SHR) = 1.03 95%CI 1.03-1.04), male gender (SHR = 1.45 95%CI 1.27-1.67), non-living donor (SHR = 1.67 95%CI 1.14-2.38), a first LT (SHR = 1.35 95%CI 1.09-1.69) and the type of initial liver disease (alcohol-related liver disease (SHR = 1.63 95%CI 1.22-2.17), primary sclerosing cholangitis (SHR = 1.98 95%CI 1.34-2.91), and primary liver tumor (SHR = 1.88 95%CI 1.41-2.54)). Initial immunosuppressive regimen had no significant impact.Conclusion: The present study confirms that LT recipient characteristics are associated with the risk ofde novo malignancy and this underlines the need for personalized screening in order to improve survival.
Published: 2020
Full Text: View/download PDF

10. Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis

Author: Laurence Chiche, Victor de Ledinghen, Marie Irles-Depe, Pauline Houssel-Debry, Martine Neau-Cransac, Sébastien Dharancy, Olivier Boillot, Jérôme Dumortier, Christophe Laurent, David Laharie, and Stéphanie Roullet
Subjects: Adult, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Cholangitis, Sclerosing, Azathioprine, 030230 surgery, Liver transplantation, Lower risk, digestive system, Gastroenterology, Inflammatory bowel disease, Primary sclerosing cholangitis, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Medicine, Humans, Retrospective Studies, Transplantation, Hepatology, business.industry, Incidence (epidemiology), Odds ratio, medicine.disease, Inflammatory Bowel Diseases, digestive system diseases, Liver Transplantation, 030211 gastroenterology & hepatology, Surgery, business, medicine.drug
Abstract: Approximately 80% of patients with primary sclerosing cholangitis (PSC) also have inflammatory bowel disease (IBD). The effect of IBD on the outcomes of liver transplantation (LT) for PSC is unclear. We retrospectively collected data from adults who underwent LT for PSC from 1989 to 2017 in four French LT centers. We compared the rates of patient and graft survivals and of complications after LT. Among 87 patients, 52 (60%) had pre-existing IBD. Excluding those who died within the first 3 months, the 10-year patient survival and graft survival rates were 92.6% (95% confidence interval [CI] 84.3-100) and 77.1% (95% CI 53.8-85.3) in the PSC with IBD (PSC-IBD) group and 97.1% (95% CI 91.4-100) (p = 0.44) and 83.2% (95% CI 69.6-96.9) (p = 0.43) in the isolated PSC group, respectively. Exposure to azathioprine after LT was significantly associated with mortality (odds ratio [OR] 15.55 [95% CI 1.31-184.0], p = 0.03), whereas exposure to mycophenolate mofetil was associated with improved survival (OR 0.17 [95% CI 0.04-0.82], p = 0.03), which may be an era effect. Exposure to cyclosporine was associated with graft loss, albeit at borderline significance: OR 3.60 [95% CI 0.96-13.42] (p = 0.06). The rate of recurrent PSC was 21% in the PSC-IBD group and 11% in the isolated PSC group (p = 0.24). The incidence of severe infection was 125 per 1000 person-years in both groups. Exposure to mycophenolate mofetil was associated with a lower risk of infection (OR 0.26 [95% CI 0.08-0.85] p = 0.03). The presence of IBD was associated with cytomegalovirus infection (OR 3.24 [95% CI 1.05-9.98], p = 0.04). The crude incidence of skin cancer was higher in the PSC-IBD group (p = 0.06). One case of colorectal cancer occurred in a patient with IBD. CONCLUSION: IBD prior to LT for PSC may not affect patient or transplant survival but may increase the risk of cytomegalovirus infection.
Published: 2020

11. Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry

Author: Christophe Duvoux, Daniel Eyraud, Rodolphe Sobesky, Guillaume Lasailly, Audrey Coilly, Sylvie Tresson, Olivier Boillot, Didier Samuel, Teresa Antonini, Valérie Cailliez, Yvon Calmus, Georges Philippe Pageaux, Martine Neau-Cransac, Faouzi Saliba, Ephrem Salamé, Eléonora Demartin, Sylvie Radenne, Jean Guguenheim, Jérôme Dumortier, Filomena Conti, Olivier Guillaud, Sébastien Dharancy, Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital Edouard Herriot [CHU - HCL], Centre Hospitalier Universitaire de Nice (CHU Nice), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), CHU Bordeaux [Bordeaux], Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (1965 - 2019) (UNS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Graft Rejection, MESH: Registries, medicine.medical_treatment, 030230 surgery, Liver transplantation, urologic and male genital diseases, 0302 clinical medicine, Registries, Graft Survival, Immunosuppression, 3. Good health, Liver, 030211 gastroenterology & hepatology, Female, MESH: Immunosuppressive Agents, France, Immunosuppressive Agents, medicine.drug, Glomerular Filtration Rate, medicine.medical_specialty, MESH: Liver Transplantation, MESH: Graft Survival, MESH: Transplant Recipients, Calcineurin Inhibitors, Urology, Renal function, MESH: Graft Rejection, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Everolimus, 03 medical and health sciences, medicine, Humans, Everolimus, Transplantation, MESH: Humans, Hepatology, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Transplant Recipients, Liver Transplantation, Calcineurin, MESH: France, Regimen, MESH: Glomerular Filtration Rate, MESH: Calcineurin Inhibitors, Surgery, business, MESH: Female, Kidney disease, MESH: Liver
Abstract: International audience; Longterm use of a calcineurin inhibitor (CNI)-based regimen is one of the major reasons for chronic renal failure in liver transplantation recipients (LTRs). The Everolimus Liver registry (EVEROLIVER) evaluated renal function in LTRs who were converted to everolimus (EVR). This observational registry included all LTRs receiving EVR across 9 centers from France. Data are being collected in an electronic database over 10 years (12 visits/patient) to evaluate efficacy, renal function (estimated glomerular filtration rate [eGFR]), and safety of EVR use in clinical practice, and the current analysis is reporting up to 60 months of findings. Until September 2017, 1045 patients received EVR after a mean time of 3.6 ± 5.1 years. CNI withdrawal was feasible in 57.7% of patients as of month 60. Mean eGFR improved in patients with baseline eGFR
Published: 2020
Full Text: View/download PDF

12. Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies

Author: Nassim Kamar, Camille Besch, Olivier Thaunat, Jérôme Dumortier, Philippe Gatault, Moglie Le Quintrec, Louise Barbier, Antoine Durrbach, Laura Lladó, Frédéric Jambon, Georges-Philippe Pageaux, Martine Neau-Cransac, Arnaud Del Bello, Oriol Bestard, Peggy Perrin, Cognata, Bérangère, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Strasbourg, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Tours (UT), Immunology from Concept and Experiments to Translation (ImmunoConcept), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Fédération Hospitalo-universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM)-Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT)-Université de Tours (UT)-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM CIC 0802 (INSERM - CHU de Poitiers), Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Edouard Herriot [CHU - HCL], CHU Toulouse [Toulouse], Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Institut National de la Santé et de la Recherche Médicale (INSERM)- Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM)-Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT)-Université de Tours (UT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Université de Poitiers, Université de Tours, Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), and Université de Tours-Université de Tours
Subjects: medicine.medical_specialty, 030232 urology & nephrology, graft survival, Ronyó, Renal function, Human leukocyte antigen, 030204 cardiovascular system & hematology, Kidney, Gastroenterology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, combined liver-kidney transplantation, 03 medical and health sciences, 0302 clinical medicine, Fetge, Clinical Research, Internal medicine, medicine, Transplantation of organs, biology, business.industry, Hazard ratio, Retrospective cohort study, donor-specific antibody, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Confidence interval, 3. Good health, Transplantation, Trasplantament d'òrgans, medicine.anatomical_structure, Rebuig (Biologia), Liver, Nephrology, Graft rejection, biology.protein, Antibody, rejection, business
Abstract: Introduction The impact of preformed donor-specific anti–human leukocyte antigen (HLA) antibodies (pDSAs) after combined liver-kidney transplantation (CLKT) is still uncertain. Methods We conducted a retrospective study in 8 European high-volume transplant centers and investigated the outcome of 166 consecutive CLKTs, including 46 patients with pDSAs. Results Patient survival was lower in those with pDSAs (5-year patient survival rate of 63% and 78% with or without pDSA, respectively; P = 0.04). The presence of pDSAs with a mean fluorescence intensity (MFI) ≥ 5000 (hazard ratio 4.96; 95% confidence interval: 2.3–10.9; P < 0.001) and the presence of 3 or more pDSAs (hazard ratio 6.5; 95% confidence interval: 2.5–18.8; P = 0.05) were independently associated with death. The death-censored liver graft survival was similar in patients with or without pDSAs. Kidney graft survival was comparable in both groups. (The 1- and 5-year death-censored graft survival rates were 91.6% and 79.5%, respectively, in patients with pDSAs and 93% and 88%, respectively, in the donor-specific antibody [DSA]-negative group, P = not significant). Despite a higher rate of kidney graft rejection in patients with pDSAs (5-year kidney graft survival rate without rejection of 87% and 97% with or without pDSAs, respectively; P = 0.04), kidney function did not statistically differ between both groups at 5 years post-transplantation (estimated glomerular filtration rate 45 ± 17 vs. 57 ± 29 ml/min per 1.73 m2, respectively, in patients with and without pDSAs). Five recipients with pDSAs (11.0%) experienced an antibody-mediated kidney rejection that led to graft loss in 1 patient. Conclusion Our results suggest that CLKT with pDSAs is associated with a lower patients’ survival despite good recipients’, liver and kidney grafts’ outcome., Graphical abstract
Published: 2020
Full Text: View/download PDF

13. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years

Author: Vincent Leroy, Christophe Duvoux, Claire Vanlemmens, Malka Tindel, Ephrem Salamé, Georges Philippe Pageaux, Yvon Calmus, Faouzi Saliba, Filomena Conti, François Durand, Hakam Gharbi, Jean Gugenheim, Jérôme Dumortier, Nassim Kamar, Jean Hardwigsen, Martine Neau-Cransac, Sébastien Dharancy, Cécile Masson, Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, CHU Henri Mondor, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Archet 2 [Nice] (CHU), CHU Toulouse [Toulouse], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Beaujon [AP-HP], CHU Saint-Eloi, Hôpital Michallon, Hôpital de la Timone [CHU - APHM] (TIMONE), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de Rangueil, Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Graft Rejection, Male, medicine.medical_specialty, Basiliximab, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Posttransplant Care, Urology, 030230 surgery, Liver transplantation, Severity of Illness Index, Tacrolimus, Mycophenolic acid, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Everolimus, Prospective Studies, Renal Insufficiency, Chronic, Aged, Randomized Controlled Trials as Topic, Sirolimus, Transplantation, Hepatology, Drug Substitution, business.industry, Graft Survival, Original Articles, Middle Aged, medicine.disease, Liver Transplantation, 3. Good health, Discontinuation, Calcineurin, Treatment Outcome, Feasibility Studies, Original Article, Female, 030211 gastroenterology & hepatology, Surgery, business, Immunosuppressive Agents, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies, medicine.drug, Kidney disease
Abstract: International audience; The observational CERTITUDE study follows liver transplant patients who completed the SIMCER trial. SIMCER randomized patients at month 1 after transplant to everolimus (EVR) with stepwise tacrolimus (TAC) withdrawal or to standard TAC, both with basiliximab induction and mycophenolic acid ± steroids. After completing SIMCER at 6 months after transplant, 65 EVR-treated patients and 78 TAC-treated patients entered CERTITUDE. At month 24 after transplant, 34/65 (52.3%) EVR-treated patients remained calcineurin inhibitor (CNI) free. Mean estimated glomerular filtration rate (eGFR) was significantly higher with EVR versus TAC during months 3-12. At month 24, eGFR values were 83.6 versus 75.3 mL/minute/1.73 m2 , respectively (P = 0.90) and adjusted mean change in eGFR from randomization was -8.0 versus -13.5 mL/minute/1.73 m2 (P = 0.15). At month 24, 45.9%, 31.1%, and 23.0% of EVR-treated patients had chronic kidney disease stages 1, 2, and 3, respectively, versus 25.7%, 45.7%, and 28.6% of TAC-treated patients (P = 0.05). Treated biopsy-proven acute rejection affected 4 EVR-treated patients and 2 TAC patients during months 6-24. Adverse events led to study discontinuation in 15.4% and 7.7% of EVR-treated and TAC-treated patients, respectively. Grade 3 or 4 hematological events were rare in both groups. A CNI-free EVR-based maintenance regimen appears feasible in approximately half of liver transplant patients. It preserves renal function effectively with good efficacy without compromising safety or hematological tolerance.
Published: 2019
Full Text: View/download PDF

14. Impact of the New MELD-based Allocation System on Waiting List and Post-Transplant Survival - A Cohort Analysis Using the French National CRISTAL Database

Author: Carine Jasseron, Claire Francoz, Corinne Antoine, Camille Legeai, François Durand, Sébastien Dharancy, null Collaborators, Christan Jacquelinet, Daniel Azoulay, Christophe Duvoux, Olivier Scatton, Yvon Calmus, Daniel Cherqui, Didier Samuel, Olivier Soubrane, Jean‐Yves Mabrut, Jérôme Dumortier, Christian Letoublon, Vincent Leroy, Denis Pezet, Armand Abergel, Antonio Iannelli, Rodolphe Anty, Francis Navarro, Georges Pageaux, François‐René Pruvot, Philippe Bachellier, Camille Besh, Georges Mantion, Vincent Di Martino, Nassim Kamar, Fabrice Muscari, Laurence Chiche, Martine Neau Cransac, Karim Boudjema, Pauline Houssel Debry, Ephrem Salame, Agence de la biomédecine [Saint-Denis la Plaine], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris 8 Vincennes-Saint-Denis (UP8), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Département de chirurgie digestive et de l'urgence, CHU Grenoble-Hôpital Michallon, Hôpital Michallon, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Strasbourg, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Chirurgie Générale et Digestive [Rangueil], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), CHU Henri Mondor [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National de la Recherche Agronomique (INRA)-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)
Subjects: medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 030230 surgery, Liver transplantation, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Intubation, allocation system, Dialysis, Transplantation, business.industry, MELD score, discriminative capacity, Post transplant, 3. Good health, body regions, Waiting list, 030211 gastroenterology & hepatology, business, survival, Cohort study
Abstract: International audience; Concerns related to equity and efficacy of our previous center-based allocation system have led us to introduce a patient-based allocation system called the "Liver Score" that incorporates the MELD score. The main objective of this study was to compare waitlist and post-transplant survivals before and after implementation of the "Liver Score" using the French transplant registry (period before: 2004-2006 and period after: 2007-2012). Patients transplanted during the second period were sicker and had a higher MELD. One-year waitlist survival (74% versus 76%; p=0.8) and one-year post-transplant survival (86.3% vs 85.7%; p=0.5) were similar between the 2 periods. Cirrhotic recipients with MELD>35 had lower one-year post-transplant survival compared to those with MELD35, patients presenting 2 or 3 risk factors (dialysis, intubation or infection) had a lower 1-year survival compared to those with none of these risk factors (61.2% vs 92%; p35 should be completed to allow safe transplantation. This article is protected by copyright. All rights reserved.
Published: 2019
Full Text: View/download PDF

15. De Novo Primary Liver Cancer After Liver Transplantation: A French National Study on 15803 Patients

Author: Manon, Allaire, Olivier, Sérée, Audrey, Coilly, Pauline, Houssel-Debry, Martine, Neau-Cransac, Georges-Philippe, Pageaux, Jérôme, Dumortier, and Mario, Altieri
Subjects: Adult, Male, Carcinoma, Hepatocellular, Time Factors, Databases, Factual, Liver Neoplasms, Middle Aged, Liver Transplantation, Immunocompromised Host, Young Adult, Treatment Outcome, Risk Factors, Humans, Female, France, Immunosuppressive Agents, Aged
Published: 2018

16. Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients

Author: Guy Launoy, Pascal Lebray, Olivier Chazouillères, Claire Francoz, Thierry Lobbedez, Sylvie Radenne, Nassim Kamar, Maryline Debette-Gratien, Sébastien Dharancy, Marie-Lorraine Woehl-Jaegle, Dominique Debray, Olivier Sérée, Jean Gugenheim, Marianne Latournerie, Vincent Leroy, Martine Neau-Cransac, Pauline Houssel-Debry, Jean Hardwigsen, Mario Altieri, Faouzi Saliba, Geraldine Hery, Olivier Boillot, Alessandra Mazzola, Rémy De Mil, Filomena Conti, Claire Vanlemmens, Georges-Philippe Pageaux, Elodie Guillaume, Philip Robinson, Emmanuel Jacquemin, Christophe Duvoux, François Durand, Ephrem Salamé, Philippe Segol, Didier Samuel, Jérôme Dumortier, Armand Abergel, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hospices Civils de Lyon (HCL), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Hôpital Edouard Herriot [CHU - HCL], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Pathologies biliaires, fibrose et cancer du foie [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de pédiatrie multidisciplinaire [Hôpital de la Timone Enfants - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor [Créteil], Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Universitaire Pontchaillou, Intéractions cellulaires et physiopathologie hépathique (Orsay, Essonne) UMRS 1174 (ICPH ), Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Equipe EPICAD (LNC - U1231), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Pôle des Pathologies Digestives Hépatiques et Transplantation [Hôpital Hautepierre-Strasbourg], Hôpital de Hautepierre [Strasbourg], Pathologies biliaires, fibrose et cancer du foie [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Université de Limoges (UNILIM)-CHU Limoges, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), CHU Henri Mondor, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), CHU Saint-Eloi, Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), and UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER
Subjects: Adult, Male, Alcoholic liver disease, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030230 surgery, Liver transplantation, Gastroenterology, Risk Assessment, Liver transplantation (LT), End Stage Liver Disease, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Risk Factors, Internal medicine, Neoplasms, medicine, Humans, education, Liver Diseases, Alcoholic, Transplantation, education.field_of_study, Hepatology, business.industry, Incidence (epidemiology), Incidence, Absolute risk reduction, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Liver Transplantation, Standardized mortality ratio, Treatment Outcome, 030211 gastroenterology & hepatology, Surgery, Female, France, Risk assessment, business, Follow-Up Studies
Abstract: IF 3.756; International audience; De novo malignancies are one of the major late complications and causes of death after liver transplantation (LT). Using extensive data from the French national Agence de la Biomédecine database, the present study aimed to quantify the risk of solid organ de novo malignancies (excluding nonmelanoma skin cancers) after LT. The incidence of de novo malignancies among all LT patients between 1993 and 2012 was compared with that of the French population, standardized on age, sex, and calendar period (standardized incidence ratio; SIR). Among the 11,226 LT patients included in the study, 1200 de novo malignancies were diagnosed (10.7%). The risk of death was approximately 2 times higher in patients with de novo malignancy (48.8% versus 24.3%). The SIR for all de novo solid organ malignancies was 2.20 (95% confidence interval [CI], 2.08‐2.33). The risk was higher in men (SIR = 2.23; 95% CI, 2.09‐2.38) and in patients transplanted for alcoholic liver disease (ALD; SIR = 2.89; 95% CI, 2.68‐3.11). The cancers with the highest excess risk were laryngeal (SIR = 7.57; 95% CI, 5.97‐9.48), esophageal (SIR = 4.76; 95% CI, 3.56‐6.24), lung (SIR = 2.56; 95% CI, 2.21‐2.95), and lip‐mouth‐pharynx (SIR = 2.20; 95% CI, 1.72‐2.77). In conclusion, LT recipients have an increased risk of de novo solid organ malignancies, and this is strongly related to ALD as a primary indication for LT.
Published: 2018
Full Text: View/download PDF

17. PS-211-Liver transplantation for HCC: Applicability and performance of the AFP score in real life. The French organization for organ sharing (ABM) experience

Author: DUVOUX, Christophe, primary, Petiet, Mathilde, additional, Oubaya, Nadia, additional, Cherqui, Daniel, additional, Pageaux, Georges-Philippe, additional, Salamé, Ephrem, additional, Radenne, Sylvie, additional, Houssel-Debry, Pauline, additional, Bachellier, Philippe, additional, Cransac, Martine Neau, additional, Francoz, Claire, additional, Muscari, Fabrice, additional, Gugenheim, Jean, additional, Filomena, CONTI, additional, claire, vanlemmens, additional, mirela, duman, additional, and Dharancy, Sebastien, additional
Published: 2019
Full Text: View/download PDF

18. Evolution of serum and intra-graft donor-specific anti-HLA antibodies in a patient with two consecutive liver transplantations

Author: Christophe Laurent, Martine Neau-Cransac, Jonathan Visentin, Brigitte Le Bail, Karine Moreau, Alice Quinart, Jean-Luc Taupin, Gwendaline Guidicelli, and Anna Boueilh
Subjects: Graft Rejection, Male, Reoperation, Pathology, medicine.medical_specialty, medicine.medical_treatment, Immunology, Cholestasis, Intrahepatic, Human leukocyte antigen, Histocompatibility Testing, Liver transplantation, Isoantibodies, HLA Antigens, medicine, Humans, Immunology and Allergy, Aged, Transplantation, medicine.diagnostic_test, biology, Antibody-Dependent Cell Cytotoxicity, Histology, Middle Aged, Immunity, Humoral, Liver Transplantation, body regions, surgical procedures, operative, Liver, Liver biopsy, biology.protein, Female, Antibody
Abstract: The current literature suggests that anti-HLA donor-specific antibodies (DSA) may have deleterious effects on liver grafts but there is no proof that they are directly involved in the graft lesions. We report the case of a donor HLA-sensitized patient who needed a second graft 6 months after the first transplantation owing to a progressive cholestatic disease that we could finally attribute to antibody-mediated rejection (AMR). We describe the longitudinal evolution of graft function, tissue histology, serum DSA and, for the first time, intra-graft DSA after elution from biopsies.
Published: 2015
Full Text: View/download PDF

19. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey

Author: Navarro, David, San-Juan, Rafael, Manuel, Oriol, Gimã©nez, Estela, FernÃ¡ndez-Ruiz, Mario, Hirsch, Hans H., Grossi, Paolo Antonio, Aguado, JosÃ© MarÃa, Abram, Maja, Abramowicz, Daniel, Ãlamo, JosÃ©-MarÃa, Alp, Sehnaz, Andres-Belmonte, Amado, Anne-Catherine, Pouleur, Antonelli, Barbara, Arnol, Miha, Arslan, Ayse Hande, Asderakis, Argiris, Baldanti, Fausto, Beneyto-Castello, Isabel, Benoit, Kabamba Mukadi, Blanes, Marino, Boggian, Katia, Bonofiglio, Renzo, Bubonja-Sonje, Marina, Caillard, Sophie, Calvo, Jorge, Capone, Alessandro, Cappelli, Gianni, Carmellini, Mario, Casafont, Fernando, Beatriz Castro-Hernandez, M., Catalan, Pilar, Celine, Bressollette-Bodin, Christoph, Berger, Cordero, Elisa, Costa, Cristina, Coussement, Julien, Cuervas-Mons, Valentin, David, Miruna, de la Torre Cisneros, Juliã¡n, Delgado, Juan F., Dello Strologo, Luca, Detry, Olivier, Dexter, Laura, Dieter, Hoffmann, Meis-HÃ¼binger, Anna, Epailly, Eric, Ericzon, Bo-Goran, Eriksson, Britt-Marie, Fehervari, Imre, Fitzgerald, Susan, Folgueira, Lola, Fortun, Jesus, Franceschini, Erica, Francois, Proot, Friman, Vanda, Frimmel, Silvius, Garzoni, Christian, Gimeno, Adelina, Gkrania-Klotsas, Effrossyni, Greer, Mark, Griffiths, Paul, Grinyã³, Josep M., Guaraldi, Giovanni, Gupte, Girish, Hammad, Abdul, Hart, Ian, Helanterã¤, Ilkka, Hellemans, Rachel, Hernã¡ndez, Domingo, Herrero, Jose Ignacio, Hiesse, Christian, Hoppe-Lotichius, Maria, Hryniewiecka, Ewa, Jaksch, Peter, Jan, Lerut, Paul, Brion Jean, Jensen-Fangel, Soren, Joerg, Steinmann, Johan, Vanhaecke, Johannessen, Ingolfur, Johansson, Inger, Kamar, Nassim, Kizilates, Filiz, Knoop, Christiane, Laurent, Belec, Lauro, Augusto, Lautenschlager, Irmeli, Lauzurica, Ricardo, Liebert, U. G., dela Monica, Paolalilla, Llado, Laura, Lopez-Andujar, Rafael, Luciani, Filippo, Maccherini, Massimo, Maertens, Johan, Maggiore, Umberto, Manrique, Alejandro, Marcos, Maria Angeles, Marekovic, Ivana, Marques, Nuno, Martin, Nitschke, Martine, Neau, Martinez-SapiÃ±a, Ana, Mateos Lindemann, M. Luisa, Mazuecos, Auxiliadora, Merino, Esperanza, Moreso, Francesc, Mueller, Nicolas, Muir, David, Mularoni, Alessandra, Muã±oz, Patricia, MuÃ±oz-Sanz, Agustãn, Nadalin, Silvio, Laura Ambra, Nicolini, Nosotti, Mario, Gorman, Joanne O., Osman, Husam, Padalko, Elizaveta, Palop-BorrÃ¡s, Begoã±a, Javirparmer, Null, Pascual, Sonia, Pena LÃ³pez, MarÃa JosÃ©, PÃ©rez-SÃ¡enz, JosÃ© Luis, Pistello, Mauro, Francisca Portero, M., Puchhammer, Elisabeth, Racca, Sara, Rahamat-Langendoen, Janette, Ramos, Antonio, Boluda, Esther Ramos, Raza, Mohammad, Regalia, Enrico, Reina, Gabriel, Reischig, Tomas, Reuter, Stefan, RodrÃguez-Ferrero, M. Luisa, Roilides, Emmanuel, Rolla, Serena, Rollag, Halvor, Rostaing, Lionel, Russo, Francesco Paolo, Sabã©, Nãºria, Saliba, Faouzi, SÃ¡nchez-Fructuoso, Ana, Scotton, Giorgio, Serra, Nuria, Sgarabotto, Dino, Stojanovic, Jelena, Tasbakan, Meltem, Telenti, Mauricio, Terhes, Gabriella, Thorban, Stefan, Tihic, Nijaz, Travi, Giovanna, Tulissi, Patrizia, Van Delden, Christian, Van Leer, Coretta, Van Loo, Inge, Varona-Bosque, MarÃa ArÃ¡nzazu, Veroux, Massimiliano, Vila-Santandreu, Ana, Waugh, Sheila, Zibar, Lada, and Zschiedr, Stefan
Subjects: 0301 basic medicine, cytomegalovirus, solid organ transplantation, survey, Cross-sectional study, Cytomegalovirus, Transplants, Practice Patterns, 030230 surgery, Organ transplantation, law.invention, 0302 clinical medicine, Postoperative Complications, law, 03.02. Klinikai orvostan, Viral, Practice Patterns, Physicians', Polymerase chain reaction, Viral Load, Europe, Infectious Diseases, Cytomegalovirus Infections, Practice Guidelines as Topic, Antibiotic Prophylaxis, Antiviral Agents, Cross-Sectional Studies, DNA, Viral, Guideline Adherence, Health Care Surveys, Humans, Immunocompromised Host, Immunosuppression, Organ Transplantation, Real-Time Polymerase Chain Reaction, Transplant Recipients, Transplantation, medicine.medical_specialty, 030106 microbiology, Congenital cytomegalovirus infection, 03 medical and health sciences, medicine, Intensive care medicine, Immunosuppression Therapy, Physicians', business.industry, DNA, medicine.disease, Molecular diagnostics, Cytomegalovirus infection, Solid organ transplantation, Survey, Immunology, business
Abstract: Background Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to an internet service provider (h t t p s://es.surveymonkey. com/) was sent to transplant physicians, transplant infectious diseases specialists, and clinical virologists working at 340 European transplant centers. Results Of the 1181 specialists surveyed, a total of 173 responded (14.8%): 73 transplant physicians, 57 transplant infectious diseases specialists, and 43 virologists from 173 institutions located at 23 different countries. The majority of centers used QNAT assays for active CMV infection monitoring. Most centers preferred commercially-available real-time polymerase chain reaction (RT-PCR) assays over laboratory-developed procedures for quantifying CMV DNA load in whole blood or plasma. Use of a wide variety of DNA extraction platforms and RT-PCR assays was reported. All programs used antiviral prophylaxis, preemptive therapy, or both, according to current guidelines. However, the centers used different criteria for starting preemptive antiviral treatment, for monitoring systemic CMV DNA load, and for requesting genotypic assays to detect emerging CMV-resistant variants. Conclusions Significant variation in CMV infection management in SOT recipients still remains across European centers in the era of molecular testing. International multicenter studies are required to achieve commutability of CMV testing and antiviral management procedures. This article is protected by copyright. All rights reserved.
Published: 2017

20. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial

Author: Christophe Duvoux, Georges Philippe Pageaux, Faouzi Saliba, Sébastien Dharancy, Jean Hardwigsen, Pauline Houssel-Debry, Yvon Calmus, D. Eyraud, Claire Vanlemmens, F. Di Giambattista, François Durand, Jean Gugenheim, Martine Neau-Cransac, Ephrem Salamé, Filomena Conti, Jérôme Dumortier, Nassim Kamar, Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Hôpital Universitaire l'Archet - Nice - France, Hôpital Universitaire Archet, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Bordeaux [Bordeaux], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Novartis Pharma SAS, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Département d'hépatologie, Novartis Pharma, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Eloi, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)
Subjects: Graft Rejection, Male, immunosuppressant, Basiliximab, medicine.medical_treatment, immunosuppression/immune modulation, 030230 surgery, Pharmacology, Liver transplantation, law.invention, 0302 clinical medicine, Postoperative Complications, Randomized controlled trial, law, Risk Factors, Immunology and Allergy, Pharmacology (medical), Prospective Studies, Graft Survival, Middle Aged, Prognosis, 3. Good health, surgical procedures, operative, 030211 gastroenterology & hepatology, Female, glomerular filtration rate (GFR), Immunosuppressive Agents, medicine.drug, medicine.medical_specialty, Randomization, Urology, clinical research/practice, Mycophenolic acid, Tacrolimus, 03 medical and health sciences, mechanistic target of rapamycin (mTOR), medicine, Humans, Everolimus, calcineurin inhibitor (CNI), Transplantation, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Mycophenolic Acid, Liver Transplantation, Calcineurin, business, liver transplantation/hepatology, Follow-Up Studies
Abstract: International audience; SIMCER was a 6-mo, multicenter, open-label trial. Selected de novo liver transplant recipients were randomized (week 4) to everolimus with low-exposure tacrolimus discontinued by month 4 (n = 93) or to tacrolimus-based therapy (n = 95), both with basiliximab induction and enteric-coated mycophenolate sodium with or without steroids. The primary end point, change in estimated GFR (eGFR; MDRD formula) from randomization to week 24 after transplant, was superior with everolimus (mean eGFR change +1.1 vs. −13.3 mL/min per 1.73 m2 for everolimus vs. tacrolimus, respectively; difference 14.3 [95% confidence interval 7.3–21.3]; p 3], graft loss, or death) from randomization to week 24 was similar (everolimus 10.0%, tacrolimus 4.3%; p = 0.134). BPAR was more frequent between randomization and month 6 with everolimus (10.0% vs. 2.2%; p = 0.026); the rate of treated BPAR was 8.9% versus 2.2% (p = 0.055). Sixteen everolimus-treated patients (17.8%) and three tacrolimus-treated patients (3.2%) discontinued the study drug because of adverse events. In conclusion, early introduction of everolimus at an adequate exposure level with gradual calcineurin inhibitor (CNI) withdrawal after liver transplantation, supported by induction therapy and mycophenolic acid, is associated with a significant renal benefit versus CNI-based immunosuppression but more frequent BPAR.
Published: 2016
Full Text: View/download PDF

21. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study

Author: Georges-Philippe Pageaux, Christophe Duvoux, Pierre Marquet, François Durand, Naila Taguieva, Faouzi Saliba, Martine Neau-Cransac, Ephrem Salamé, Gilles Sinnasse-Raymond, Mylène Sebagh, Lionel Rostaing, Sylvie Radenne, Vincent Leroy, Jean Gugenheim, Didier Samuel, and Yvon Calmus
Subjects: Adult, Graft Rejection, Male, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Biopsy, Calcineurin Inhibitors, Urology, chemical and pharmacologic phenomena, 030230 surgery, Liver transplantation, Mycophenolate, Mycophenolic acid, Tacrolimus, law.invention, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Randomized controlled trial, law, Adrenal Cortex Hormones, Risk Factors, medicine, Humans, Prospective Studies, Aged, Transplantation, business.industry, Graft Survival, Middle Aged, Mycophenolic Acid, 3. Good health, Liver Transplantation, Calcineurin, Regimen, surgical procedures, operative, Treatment Outcome, Corticosteroid, Feasibility Studies, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, France, Drug Monitoring, business, Immunosuppressive Agents, medicine.drug
Abstract: We conducted a randomized multicenter open-label trial in de novo liver transplant recipients to assess the feasibility and potential benefit of a corticosteroid (CS)-free regimen coupled with tacrolimus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individually.Adult liver transplant recipients were randomized on the day of transplantation to a CS-free regimen with Tac and MMF starting at 3 g/d and dose adjusted from day 5 according to mycophenolic acid (MPA) exposure (arm A) or a regimen with CS maintained up to 6 months, Tac and fixed-dose MMF (2 g/d) (arm B). The primary end point was the proportion of patients who experienced treated biopsy-proven acute rejection (BPAR) during the first year posttransplant.One hundred eighty-seven patients were randomized, and 174 comprised the per-protocol population (87 in each arm). The primary objective of noninferiority was met: 7 patients in arm A (8%) and 8 in arm B (9%) experienced treated BPAR in the first year. Two patients in arm A (2%) and 5 in arm B (6%) lost their graft, and 12-month patient survival was similar in both arms (90.8% vs 89.8%; P = 0.86). Adverse events were comparable between arms, except for a lower incidence of de novo diabetes (19.8% vs 32.6%, P = 0.049) and a higher incidence of leukopenia less than 2000/mm (28.6% vs 9.8%; P = 0.001) and neutropenia (26.7% vs 7.9%; P0.001) in arm A.Mycophenolate mofetil at intensified and individually adjusted dose in combination with Tac in de novo liver transplant recipients allows CS discontinuation from day 1 posttransplant with good tolerance and very low rejection incidence.
Published: 2016

22. Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis

Author: Faouzi Saliba, Sébastien Dharancy, R. Lorho, Yvon Calmus, Filomena Conti, Monika Hurtova, Martine Neau-Cransac, Jean Hardwigsen, Jérôme Dumortier, and Sylvie Radenne
Subjects: Transplantation, medicine.medical_specialty, Creatinine, Everolimus, Hepatology, business.industry, medicine.medical_treatment, Urology, Renal function, Retrospective cohort study, Liver transplantation, Surgery, Calcineurin, chemistry.chemical_compound, chemistry, medicine, Trough level, business, medicine.drug
Abstract: Data on the conversion of patients to everolimus after liver transplantation are sparse. A multicenter, retrospective study followed 240 maintenance liver transplant patients to analyze the current indications for everolimus conversion, the employed regimens and exposure levels, and the impact on efficacy and safety. The mean time from transplantation to the introduction of everolimus was 4.9 ± 5.2 years. The mean everolimus trough level was 7.3 ± 4.1 ng/mL at month 1 and 8.1 ± 4.7 ng/mL at month 12. At 12 months, 61.6% of the patients were no longer receiving calcineurin inhibitor (CNI) therapy. The mean estimated glomerular filtration rate (eGFR) according to the Cockcroft-Gault formula was 64.2 ± 30.0 mL/minute on day 0 and 68.4 ± 32.5 mL/minute at month 12 (P = 0.007). Among patients with baseline serum creatinine levels ≥ 130 μmol/L, the eGFR values were 44.3 ± 15.7 mL/minute on day 0 and 53.7 ± 26.0 mL/minute at month 12 (P = 0.003). Four patients (1.6%) developed mild or moderate biopsy-proven acute rejection. Adverse events led to everolimus discontinuation in 12.9% of the patients. After the initiation of everolimus, the mean white blood cell count decreased significantly, and the total cholesterol and triglyceride levels increased significantly. In this retrospective analysis of the largest cohort of maintenance liver transplant patients analyzed after their conversion to everolimus, more than 60% of the patients were kept free of CNIs with a very low risk of acute rejection and with an acceptable safety profile. Randomized trials in which maintenance liver transplant patients are switched to everolimus in response to clinical indications or preemptively are warranted. Liver Transpl 17:905–913, 2011. © 2011 AASLD.
Published: 2011
Full Text: View/download PDF

23. Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients

Author: Laurence Dubel, Nassim Kamar, Yvon Calmus, Philippe Wolf, Christian Ducerf, Christophe Duvoux, Olivier Chazouillères, Lionel Rostaing, Martine Neau-Cransac, Ephrem Salamé, Nicole Declerck, Didier Samuel, Claire Vanlemmens, Jean Gugenheim, and Georges-Philippe Pageaux
Subjects: Adult, Male, medicine.medical_specialty, Daclizumab, Time Factors, medicine.medical_treatment, Urology, Renal function, chemical and pharmacologic phenomena, Liver transplantation, Antibodies, Monoclonal, Humanized, Tacrolimus, Humans, Medicine, Antibacterial agent, Transplantation, business.industry, Incidence, Liver Diseases, Antibodies, Monoclonal, Middle Aged, Mycophenolic Acid, medicine.disease, Liver Transplantation, Surgery, Calcineurin, surgical procedures, operative, Liver, Creatinine, Immunoglobulin G, Female, Steroids, business, Immunosuppressive Agents, Kidney disease, medicine.drug
Abstract: Calcineurin inhibitor-induced renal dysfunction is a major problem in liver transplantation. Interleukin-2 receptor antagonist induction followed by delayed tacrolimus (Tac) administration may minimize the renal insult without compromising immunoprotection.This open, randomized, multicenter trial evaluated the benefit of daclizumab induction with delayed Tac on renal function at 6 months; an observational study was continued for 18 months. Liver transplant patients with a 12-hr serum creatinine (SrC) level less than 180 micromol/L received either delayed Tac with daclizumab induction (n=98) or standard Tac (n=101) both combined with mycophenolate mofetil and steroids. The primary endpoint was the incidence of SrC level more than 130 micrommol/L at 6 months.The incidence was 22.4% with delayed Tac and 29.7% with standard Tac (P=ns), which remained unchanged at 12 months (21.6% and 23.9%) but increasing slightly at 24 months (29.0% and 32.9%), respectively. A post hoc analysis of renal function was done based on patients stratification by SrC at 12 hr (or=100micromol/L or100 micromol/L) showing no difference in SrC values at 6 months regardless of the 12-hr values despite a trend toward better estimated glomerular filtration rate for patients with 12-hr value less than 100 micromol/L in the delayed Tac group. Biopsy-proven acute rejection was similar at 6 months (17.5% and 18.75%), 12 months (23.5% and 23.8%), and 24 months (24.5% and 25.7%), respectively. Patient and graft survival in both groups were comparable and good. Similar types and incidences of adverse events were reported in both groups at all time.Delay of Tac does not benefit renal function in liver transplant recipients with a good renal function at baseline.
Published: 2010
Full Text: View/download PDF

24. Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients

Author: Lionel Couzi, Claire Dromer, Anne Caumont, Marie-Edith Lafon, Sébastien Boucher, Martine Neau-Cransac, Hervé Fleury, Marie-Hélène Schrive, Reza Tabrizi, and Isabelle Garrigue
Subjects: Adult, Male, Population, Congenital cytomegalovirus infection, Cytomegalovirus, Sensitivity and Specificity, law.invention, Viral Matrix Proteins, law, Betaherpesvirinae, Virology, medicine, Humans, education, Polymerase chain reaction, Bone Marrow Transplantation, Whole blood, education.field_of_study, biology, Reverse Transcriptase Polymerase Chain Reaction, Organ Transplantation, Middle Aged, Reference Standards, Viral Load, Phosphoproteins, biology.organism_classification, medicine.disease, Transplantation, Infectious Diseases, Real-time polymerase chain reaction, Evaluation Studies as Topic, Cytomegalovirus Infections, DNA, Viral, Immunology, Female, Viral load, Follow-Up Studies
Abstract: Background Cytomegalovirus (CMV) remains a major opportunistic agent among transplant recipients. While detection of CMV pp65-lower matrix protein (pp65Ag) is still widely used for monitoring CMV infection, real-time PCR assays have been recently developed for routine quantitation of CMV DNA. However, correlations are lacking between results of pp65Ag and quantitative PCR assays and there is no consensus yet as to the more appropriate blood compartment (whole blood (WB), leukocytes, plasma) to be tested with PCR assays. Objectives The aims of the study were to determine, in a population of transplant recipients: (i) the correlation between pp65Ag and CMV quantitative real-time PCR in our setting and (ii) the utility of plasma CMV DNA quantitation in comparison to WB quantitation. Methods In 170 blood samples (from 61 solid organ or bone marrow transplant recipients) with pp65Ag results, CMV quantitation was performed in WB and plasma using an in-house real-time quantitative PCR. Results Real-time PCR and pp65Ag results in WB were correlated: thresholds of 10 and 50(+) cells/200,000 cells were equivalent to 3.3 log10 copies/mL (2000 copies/mL) and 3.8 log10 copies/mL (6300 copies/mL), respectively. When WB viral load was ≥3.6 log10 copies/mL, the risk to have a negative plasma CMV DNA result was ≤2.5%. Conclusions For the routine exploration of a single compartment, whole blood would represent a suitable compromise: easy processing for a sensitive assay. The 3.6 log10 copies/mL threshold, which could help in identifying active CMV infection, deserves further evaluation.
Published: 2006
Full Text: View/download PDF

25. Once-daily prolonged release tacrolimus in liver transplantation: Experts' literature review and recommendations

Author: Olivier Guillaud, Pauline Houssel-Debry, Audrey Coilly, Faiza Chermak, Christophe Duvoux, Martine Neau-Cransac, Yvon Calmus, Jérôme Dumortier, Jeanick Stocco, Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], service d'Hépato-gastro-entérologie, Hospices Civiles de Lyon-Hôpital Edouard Heriault, Pôle Recherche Clinique-Santé Publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies du foie, Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Jonchère, Laurent, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies du foie [CHU Rennes], and Centre Hospitalier Universitaire [Rennes]
Subjects: Graft Rejection, medicine.medical_specialty, Time Factors, Dose, Chemistry, Pharmaceutical, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Urology, Context (language use), 030230 surgery, Liver transplantation, Pharmacology, Drug Administration Schedule, Tacrolimus, Medication Adherence, Food-Drug Interactions, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, medicine, Humans, Transplantation, Hepatology, medicine.diagnostic_test, business.industry, Graft Survival, Area under the curve, Liver Transplantation, 3. Good health, [SDV] Life Sciences [q-bio], stomatognathic diseases, Treatment Outcome, Therapeutic drug monitoring, Delayed-Action Preparations, Concomitant, Practice Guidelines as Topic, Trough level, 030211 gastroenterology & hepatology, Surgery, Drug Monitoring, business, Immunosuppressive Agents
Abstract: International audience; The efficacy and safety of tacrolimus (Tac) twice daily (bid) and once a day (qd) formulations are considered to be similar. However, the available information regarding initiation of Tac qd is sparse, and practical information is lacking. On the basis of a literature review, clinical efficacy, and safety trials, French experts in the liver transplantation field were asked to highlight pharmacokinetic (PK) differences between both formulations to assess efficacy and safety of the qd formulation in the context of de novo initiation or conversion and to provide their recommendations for initiation and day-to-day management of Tac qd. The same efficacy and safety profile is found for both immediate-release and prolonged-release Tac. PK differences carry on absorption because of the difference in formulations but not on metabolism or excretion. Tac qd offers a better reproducibility in exposure than Tac bid but is associated with an increased risk of disturbed absorption in case of a change in intestinal motility. The same therapeutic drug monitoring with Tac qd and bid could be applied, based on minimal concentration (trough level; Cmin ), as there is a similar strong correlation between Cmin and the area under the curve (AUC) for both formulations. Different protocols for Tac qd initiation were described through numerous studies, except for early conversion: initiation on day 0, using 0.10 to 0.20 mg/kg/day as monotherapy, or lower dosages in case of concomitant immunosuppressant treatment or poor graft quality; early conversion from day 5 to 6 months, preferably before hospital discharge, using a 1 to 1.3 mg/kg/day schedule and with first Cmin assessment 48 hours after the conversion; and later conversion (\textgreater6 months posttransplantation) using a milligram-to-milligram dosage schedule, and with dose adjustment based on weekly Cmin measurement. Experts underline that an increase in treatment adherence was expected using Tac qd in liver recipients. In conclusion, Tac qd has the same efficacy and safety profile as Tac bid. De novo introduction or later conversion are well documented but could differ from day-to-day practice. Liver Transpl 21:1312-1321, 2015. © 2015 AASLD
Published: 2015
Full Text: View/download PDF

26. γδ T Lymphocytosis Associated with Granulomatous Disease in a Patient with Common Variable Immunodeficiency

Author: Olivier Caubet, Marie Parrens, Jean-Luc Pellegrin, Jean-Luc Taupin, Coralie Bloch-Michel, Jean-François Moreau, Jeannette Texier-Maugein, Jean-François Viallard, and Martine Neau-Cransac
Subjects: Adult, Microbiology (medical), Pathology, medicine.medical_specialty, CD3 Complex, T-Lymphocytes, CD3, Immunoglobulin Isotypes, Lymphocytosis, Granulomatous Disease, Chronic, Immunodeficiency Syndrome, medicine, Humans, biology, business.industry, Common variable immunodeficiency, T-cell receptor, Receptors, Antigen, T-Cell, gamma-delta, T lymphocyte, medicine.disease, Common Variable Immunodeficiency, Infectious Diseases, Granuloma, Immunology, biology.protein, Female, Antibody, business
Abstract: Common variable immunodeficiency (CVID) is a heterogeneous group of immunodeficiency syndromes that involves defective production of specific antibodies and decreased serum concentrations of > or =1 immunoglobulin isotype. We describe a patient with an atypical case of CVID who had extensive granulomatous lesions that were partially attributable to mycobacterial infection. In the peripheral blood, there was a massive increase in the number of double-negative CD3+ T cells that expressed the gammadelta T cell receptor.
Published: 2002
Full Text: View/download PDF

27. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal

Author: Delphine Morel, Pierre Merville, Pierre-Henri Bernard, Jean Saric, Luc Potaux, Philippe Revel, and Martine Neau-Cransac
Subjects: Transplantation, medicine.medical_specialty, Kidney, business.industry, medicine.medical_treatment, Urology, Liver transplantation, medicine.disease, Ciclosporin, Tacrolimus, Mycophenolic acid, Surgery, Calcineurin, surgical procedures, operative, medicine.anatomical_structure, medicine, business, Kidney disease, medicine.drug
Abstract: Chronic nephrotoxicity is one of the most serious side-effects of calcineurin inhibitor treatment and a factor in mortality and morbidity after liver transplantation. In our transplant centre, among patients who underwent a liver transplantation between January 1989 and December 2000, 14 liver graft recipients (6.86%) developed de novo severe renal dysfunction as defined by a serum creatinine concentration above 200 micromol/L. Renal biopsy was performed in nine cases and evidenced histological lesions compatible with chronic nephrotoxicity related to calcineurin inhibitor treatment. For nine patients, we report the results of a prospective non-randomized study consisting of cyclosporine or tacrolimus withdrawal associated with administration of mycophenolate mofetil or azathioprine. Despite this therapeutic modification, we did not observe a significant renal function improvement but on the other hand, there was no graft rejection.
Published: 2002
Full Text: View/download PDF

28. Gamma-delta T cell expansion is closely associated with cytomegalovirus infection in all solid organ transplant recipients

Author: Marc-Alain Billes, Julie Déchanet-Merville, Xavier Lafarge, Lionel Couzi, Vincent Pitard, Florence Lacaille, Claire Dromer, Jean-François Moreau, Pierre Merville, and Martine Neau-Cransac
Subjects: Cytomegalovirus infection, Transplantation, medicine.anatomical_structure, business.industry, Immunology, Medicine, business, Gamma delta T cell, Solid organ transplantation
Published: 2011
Full Text: View/download PDF

29. Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays

Author: Martine Neau-Cransac, Sophie Daburon, Jonathan Visentin, Cécile Contin-Bordes, Véronique Frémeaux-Bacchi, Jean-Luc Taupin, Gwendaline Guidicelli, Margaux Vigata, Marc-Alain Billes, and Claire Dromer
Subjects: Hereditary Complement Deficiency Diseases, medicine.drug_class, Human leukocyte antigen, Plasma protein binding, Monoclonal antibody, Complement factor B, Immunoglobulin G, HLA Antigens, medicine, Complement C4b, Humans, Complement Activation, Edetic Acid, Immunoassay, Transplantation, biology, Chemistry, Complement C1q, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, Immunologic Deficiency Syndromes, Antibodies, Monoclonal, Complement C3, Complement System Proteins, Molecular biology, Peptide Fragments, Complement system, Complement C3d, biology.protein, Alternative complement pathway, Antibody, Protein Binding
Abstract: Background Anti-human leukocyte antigen (HLA) antibody detection in solid-phase flow beads assays can be quenched by complement activation, but the precise mechanism of this interference is not fully elucidated yet. Methods Using the Luminex flow beads screening assay for detection of anti-HLA antibodies, we analyzed the binding of high concentrations of the pan class I anti-HLA monoclonal antibody W6/32 in neat normal, ethylenediaminetetraacetic acid-treated normal and complement factors C1q, C4/C3, C2, C3, factor B or C5-depleted human sera, using anti-mouse immunoglobulin G as the detection antibody. Complement activation and binding to beads were revealed using anti-human C1q, C4d, and C3d antibodies. To translate our findings to the human setting, we used the class I and class II HLA single-antigen flow beads assays and sera from four patients with high titers of antibodies. Results Detection of W6/32 did not suffer any interference with C1q and C4/C3-depleted sera. A partial quenching was observed with C2, C3, and factor B-depleted sera, but was more pronounced with the factor B-depleted serum. W6/32 was undetectable in presence of C5-depleted serum. The binding of activation products derived from C3 principally, and also from C4, impaired immunoglobulin G and C1q detection. Accordingly, C4d detection was hindered by deposition of activated C3. Similar findings were obtained with patients' sera. Conclusion Binding of C4 and C3 activation products is the main responsible for complement interference in flow beads assays. A complete quenching requires complement activation through C3 cleavage and its amplification by the alternative pathway.
Published: 2014

30. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors

Author: Estelle Juinier, Pierre Merville, Gwendaline Guidicelli, Marc-Alain Billes, Claire Dromer, Jean-Luc Taupin, Emma Perbos, and Martine Neau-Cransac
Subjects: Graft Rejection, Male, medicine.medical_specialty, Calcineurin Inhibitors, Urology, Organ transplantation, HLA Antigens, Isoantibodies, Risk Factors, medicine, Humans, Everolimus, Prospective Studies, Retrospective Studies, Sirolimus, Transplantation, Kidney, Lung, biology, Dose-Response Relationship, Drug, business.industry, Drug Substitution, Incidence (epidemiology), Histocompatibility Testing, Graft Survival, Organ Transplantation, Middle Aged, Prognosis, Tissue Donors, Transplant Recipients, Surgery, Calcineurin, medicine.anatomical_structure, Case-Control Studies, biology.protein, Drug Therapy, Combination, Female, Antibody, business, Immunosuppressive Agents, medicine.drug, Follow-Up Studies
Abstract: Background Everolimus (EVR) is used in organ transplantation to minimize calcineurin inhibitors (CNI). Some studies pointed out an increase in rejection and de novo donor-specific antibodies (DSA) incidence in kidney transplant patients after switch to EVR and CNI withdrawal. The aims of our study were to determine the evolution of anti-HLA antibodies and the incidence of de novo DSA in transplant recipients after conversion to EVR. Methods Heart, lung, kidney, and liver transplant recipients were included in a retrospective, monocentric case–control study. Anti-HLA antibodies were identified at transplantation, pre-switch, and at three, six, and 12 months post-switch. Results Conversion to EVR was performed about six yr after the transplant, and low-dose CNI was maintained in 60% of patients. We found no statistical difference for rejection, evolution of preformed anti-HLA antibodies or de novo DSA, after conversion to EVR or not. Incidence of anti-class II DSA tended to increase at month 12 whatever the immunosuppressive regimen. Conclusions Late conversion to EVR appears to be safe and to not modify the natural evolution of anti-HLA antibodies in organ transplantation. As 60% of patients received EVR and low doses of CNI, it seems that such combinations could be used with a good outcome.
Published: 2014

31. Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation

Author: Daniel Cherqui, Olivier Boillot, Jacques Belghiti, Jean Gugenheim, Philippe Wolf, M. Messner, Georges Philippe Pageaux, Yvon Calmus, Y Le Treut, Jacques Baulieux, Martine Neau-Cransac, and Didier Samuel
Subjects: Transplantation, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunosuppression, Azathioprine, Liver transplantation, Gastroenterology, Surgery, Regimen, Internal medicine, Cohort, medicine, Prospective cohort study, business, Survival rate, medicine.drug
Abstract: We studied the outcome of 345 liver transplant patients who received tacrolimus-based immunosuppressive therapy either as a dual regimen (with corticosteroids, n=172) or as a triple regimen (with corticosteroids and azathioprine, n=173) for 3 months after transplantation (3-month cohort). A further analysis was conducted for the first 195 patients randomised (dual n=100, triple n=95) who were followed up for 12 months after transplantation (12-month cohort). For the 3-month cohort, patient survival was 90.7% (dual) and 91.9% (triple), graft survival after 3 months was 88.4% (dual therapy) and 89.6% (triple therapy). Acute rejections were experienced by 67/172, 39.0% of patients on dual therapy and by 60/173, 34.7% of patients on triple therapy; corticosteroid-resistant rejections were reported in 9 patients (5.2%) in either treatment group. The overall safety profile was similar for the two treatment groups. Significant differences, however, were found for thrombocytopenia (dual 13/172, 7.6%, triple 37/173, 21.4%, p
Published: 2001
Full Text: View/download PDF

32. Recurrence and Accelerated Progression of Hepatitis C following Liver Transplantation

Author: Anne Rullier, Pascale Trimoulet, P. Bioulac-Sage, C. Balabaud, Martine Neau-Cransac, B. Le Bail, and Pierre-Henri Bernard
Subjects: Graft Rejection, medicine.medical_specialty, medicine.medical_treatment, macromolecular substances, Liver transplantation, Antibodies, Viral, Gastroenterology, Virus, Diagnosis, Differential, chemistry.chemical_compound, Recurrence, Internal medicine, Biopsy, medicine, Humans, Transaminases, Aged, Hepatitis, Hepatology, medicine.diagnostic_test, business.industry, Ribavirin, Bilirubin, Hepatitis C, Viral Load, Hepatitis B, medicine.disease, Immunohistochemistry, Liver Transplantation, chemistry, Hyperglycemia, DNA, Viral, Hypertension, Disease Progression, Female, business, Viral load, Immunosuppressive Agents
Abstract: The patient described had recurrent hepatitis C following OLT. This hepatitis appeared early postOLT and progressed to fibrosing cholestatic hepatitis, a severe form of HCV recurrence. Factors such as genotype 1, high viral load and severe damage on the first postOLT biopsy may indicate a more severe outcome. We have hypothesized that, in parallel to what is known for hepatitis B, this rare form of recurrence was linked to a high expression of virus C proteins in the liver graft. Severe form of hepatitis C recurrence should be treated early with the best currently available treatment which is a combination of IFN and ribavirin. Large series of patients with comparable virological, histological and immunological inclusions criteria are necessary to evaluate the efficacy of this treatment.
Published: 2000
Full Text: View/download PDF

33. Contents Vol. 211, 2005

Author: Christos C. Zouboulis, M. Monika Weber, Selim Aractingi, Venkata Putcha, Isabelle Daigle, M.A. Duchosal, J.L. Arranz López, Hiroyuki Matsue, E. Gambillara, Jann Lübbe, D.A. Fairhurst, P. Dellamonica, Christian Surber, Dominique Bonneau, Emmanuel Laffitte, Olivier Sorg, Katrin Kerl, Dan Lipsker, Karin Thoss, Wolfram Sterry, Henrik Møller, Maria Morales, E. Counillon, Alice Quinart, P. Del Giudice, Andreas J. Bircher, Mohammad Reza Fallahi, Agustin Llopis, Uwe Trefzer, Alexander C. Katoulis, Jean-Hilaire Saurat, Nicholas G. Stavrianeas, Jørn Olsen, Marc Buffet, Pierre Carraux, Thomas J. Brill, N. Kunzle, Mohammad Nikbakhsh, Hans-Peter Baum, J.-H. Saurat, Ambros Hügin, M. Grelier, Paulette Bioulac-Sage, Naohito Hatta, Farshad Farnaghi, Lutz Kowalzick, Philippe Revel, Carol M. Artlett, Gholamhosein R. Omrani, T. Rodriguez Bravo, Sébastien Lepreux, Katharina Spanaus Schlapbach, Carolina Pellanda, Günter Burg, Günther F.L. Hofbauer, Christine Labreze, N. Widmer, H. Zeller, Jürgen Quietzsch, Hassan Seirafi, A. Carlotti, I. Schuffenecker, Sylvie De Maricourt, Luca Borradori, Rahman Nazari, Sofia Georgala, Roland Blum, Laurence Doelker, Christian Tran, Emmanuel Molinari, Christophe Antille, Jürgen Lademann, Akiko Nagasaka, I. Masouyé, P. Lesavre, Mitra Amini, J.-M. Pönnighaus, Renato G. Panizzon, Amin Parhizgar, L.A. Decosterd, H. Zachariae, Daniel Mischke, S.M. Clark, Julie De Quatrebarbes, E. Laffitte, Ute Jacobi, Evelyne Leemans, Giovanni Luigi Capella, Diamant Thaçi, Nicolas Dupin, Hans-Uwe Simon, Reinhard Dummer, Eva M. Valesky, Julien Gautier, Denise Grand, Behrooz Kasraee, Jörg Willers, Thierry André, F. Vandenbos, T. Kovacsovics, Parisa Mansoori, Aiko Miyahara, Heidrun Ziegler, L. Garcia Martinez, Gürkan Kaya, Shinji Shimada, Julien Autier, J.-P. Venetz, Farhad Handjani, M. Pascual, Roland Kaufmann, Thomas Elshorst-Schmidt, Arash Taheri, Regina Treudler, Martine Neau-Cransac, Pierre Vabres, E. Elena Sorando, Maryam Akhyani, Jean Saric, Helen S. Evans, Isabelle Gorin, and Silvio Hemmi
Subjects: Dermatology
Published: 2005
Full Text: View/download PDF

34. Uncommon Localization of Calcinosis Cutis after Liver Transplantation

Author: Martine Neau-Cransac, Sébastien Lepreux, Alice Quinart, C. Labreze, Jean Saric, Philippe Revel, and Paulette Bioulac-Sage
Subjects: Calcinosis cutis, medicine.medical_specialty, Biphosphonate, business.industry, medicine.medical_treatment, medicine, Dermatology, Liver transplantation, business, medicine.disease
Published: 2005
Full Text: View/download PDF

35. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin

Author: Philippe Wolf, Didier Samuel, Karim Boudjema, Christophe Duvoux, Lionel Rostaing, Olivier Boillot, Claire Vanlemmens, Yvon Calmus, Martine Neau-Cransac, Jean Gugenheim, Danielle Botta-Fridlund, Georges Philippe Pageaux, François Durand, Olivier Chazouillères, Sébastien Dharancy, L. Samelson, Service de Chirurgie Digestive, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pôle Recherche Clinique-Santé Publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service de Chirurgie Générale et Transplantation Multi Organes, CHU Strasbourg, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Service d'hépatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Claude Hurriez, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), French National Direction for Clinical Research (Direction de la Recherche Clinique), Roche Pharma France., CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Service d'hépatologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: Liver Cirrhosis, Male, medicine.medical_treatment, MESH: Logistic Models, Hepacivirus, Liver transplantation, Kidney, Gastroenterology, MESH: Cyclosporine, Polyethylene Glycols, Placebos, MESH: Recombinant Proteins, MESH: Genotype, chemistry.chemical_compound, 0302 clinical medicine, Maintenance therapy, Recurrence, MESH: Double-Blind Method, MESH: Hepacivirus, MESH: Treatment Outcome, 0303 health sciences, MESH: Middle Aged, Hepatitis C virus, virus diseases, Hepatitis C, Induction Chemotherapy, Middle Aged, Viral Load, MESH: Induction Chemotherapy, Recombinant Proteins, 3. Good health, MESH: Maintenance Chemotherapy, Treatment Outcome, Cyclosporine, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, MESH: Immunosuppressive Agents, MESH: Interferon-alpha, MESH: Liver Cirrhosis, MESH: Viral Load, Viral load, Immunosuppressive Agents, MESH: Antiviral Agents, medicine.medical_specialty, MESH: Liver Transplantation, Combination therapy, Genotype, MESH: Placebos, Placebo, Antiviral Agents, Tacrolimus, Maintenance Chemotherapy, 03 medical and health sciences, Double-Blind Method, MESH: Ribavirin, Internal medicine, Viral response, Ribavirin, medicine, MESH: Tacrolimus, Humans, Peginterferon, Erythropoietin, 030304 developmental biology, MESH: Hepatitis C, Intention-to-treat analysis, MESH: Humans, Hepatology, business.industry, Interferon-alpha, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Kidney, medicine.disease, Fibrosis, digestive system diseases, MESH: Male, Liver Transplantation, MESH: Recurrence, MESH: Drug Therapy, Combination, Logistic Models, chemistry, MESH: Polyethylene Glycols, Immunology, business, MESH: Female
Abstract: International audience; BACKGROUND & AIMS: We aimed at determining the effect of maintenance therapy with ribavirin alone, after a year of combined peginterferon-alfa 2a (PegIFNα-2a) and ribavirin therapy, on viral response and liver histology after liver transplantation (LT). METHODS: Hundred and one patients with recurrent HCV and a minimum of stage 1 fibrosis (METAVIR scoring), 1-5years after LT, were enrolled. PegIFNα-2a and ribavirin were initiated at 90 μg/wk and 600 mg/d, respectively, then increased or adjusted as a function of tolerance. At 12 months, combination therapy was discontinued and patients were randomized to ribavirin or placebo for a further 12 months. Growth factor use was permitted. RESULTS: At 18 months, a sustained virological response (SVR) was obtained in 47.9% of patients in Per Protocol (PP) analysis, and was higher in patients with genotype 2 or 3 than in patients with genotype 1 or 4, in patients with genotypes 1+4 receiving ciclosporine than in those receiving tacrolimus, in patients with worse renal function, in those having received EPO, in patients with lower weight, and in those with lower viral load at 3 months. Using logistic regression, only the early viral response, recipient weight and renal function were independently associated with better SVR. SVR, viral load, activity, and fibrosis scores were similar, at M18 and M30, in patients randomized to ribavirin, or to placebo. CONCLUSIONS: A PP SVR was achieved in 47.9% of patients with established recurrent hepatitis C after LT. Maintenance therapy with ribavirin alone does not improve the virological response or the histological parameters.
Published: 2012
Full Text: View/download PDF

36. Disseminated Mycobacterium avium Infection after Liver Transplantation

Author: J. Carles, B. Le Bail, Jean Saric, Michel Dupon, and Martine Neau-Cransac
Subjects: Microbiology (medical), medicine.medical_specialty, Opportunistic infection, medicine.medical_treatment, Mycobacterium Avium Infection, General Medicine, Middle Aged, Opportunistic Infections, Biology, Liver transplantation, medicine.disease, Virology, Liver Transplantation, Transplantation, Immunocompromised Host, Infectious Diseases, Medical microbiology, Immunology, medicine, Humans, Tuberculosis, Female, Complication, Mycobacterium avium
Published: 1998
Full Text: View/download PDF

37. Tacrolimus (FK506)-Based Dual Versus Triple Therapy Following Liver Transplantation

Author: Didier Samuel, J Pageaux, Christophe Duvoux, Bernard Launois, P Campan, Jacques Belghiti, Martine Neau-Cransac, H. Bismuth, Jean Saric, P.P Massault, François Durand, Y LeTreut, E Ellero, Olivier Boillot, Daniel Cherqui, Elizabeth H. Baldini, Jacques Domergue, Yvon Calmus, Christian Ducerf, J Gugenheim, Philippe Wolf, M. Messner, and Jacques Baulieux
Subjects: Adult, Graft Rejection, Male, medicine.medical_specialty, Adolescent, medicine.drug_class, medicine.medical_treatment, Urology, Azathioprine, Liver transplantation, Methylprednisolone, Tacrolimus, Pharmacotherapy, Cause of Death, Humans, Medicine, Survival rate, Aged, Transplantation, business.industry, Graft Survival, Middle Aged, Liver Transplantation, Surgery, Survival Rate, Corticosteroid, Drug Therapy, Combination, Female, business, Immunosuppressive Agents, medicine.drug
Published: 1998
Full Text: View/download PDF

38. Plasma and Liver Hepatitis C Virus Variability in Patients Coinfected with Human Immunodeficiency Virus

Author: Marie-Edith Lafon, Christophe Martinaud, Muriel Faure, Martine Neau, Michel Dupon, Anne-Christine Jouvencel, Elisabeth Legrand, Didier Neau, Hervé Fleury, Brigitte Le Bail, Jean-Marie Ragnaud, Pascale Trimoulet, Isabelle Garrigue, and Paulette Bioulac-Sage
Subjects: Microbiology (medical), Genotype, Hepacivirus, Hepatitis C virus, Viremia, HIV Infections, medicine.disease_cause, Virus, Flaviviridae, Interferon, Virology, medicine, Humans, biology, virus diseases, Genetic Variation, Hepatitis C, medicine.disease, biology.organism_classification, digestive system diseases, Liver, Organ Specificity, Case-Control Studies, Immunology, Viral disease, Interferons, medicine.drug
Abstract: Liver and plasma hepatitis C virus (HCV) variability was compared by E2 cloning and sequencing in three patients coinfected with HCV and human immunodeficiency virus (HIV) before and after interferon treatment and in three patients solely infected with HCV. The plasma and liver samples contained unique sequences. In the patients coinfected with HIV, accumulated random mutations produced mostly nonsynonymous substitutions in contrast to the reduced HCV genetic variability seen after treatment.
Published: 2006

39. Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection

Author: Victor de Ledinghen, Martine Neau-Cransac, Marie-Edith Lafon, Juliette Foucher, Pierre-Henri Bernard, and Elisabeth Legrand
Subjects: Adult, Male, Time Factors, Lymphocyte, CD3, T-Lymphocytes, Immunology, Antiviral Agents, chemistry.chemical_compound, Chronic hepatitis, Interferon, Antigens, CD, Virology, Ribavirin, Medicine, Humans, Lymphocyte Count, Total Lymphocyte Counts, biology, business.industry, HLA-DR Antigens, Hepatitis C, Chronic, Middle Aged, Recombinant Proteins, medicine.anatomical_structure, chemistry, Interferon Type I, biology.protein, Molecular Medicine, Female, business, CD8, medicine.drug, Lymphocyte subsets
Abstract: Our purpose was to determine in HCV-infected patients whether T-lymphocyte sub-populations were modified before and during interferon-alpha and ribavirin treatment, and whether this correlated with virological response. Twenty-two naive patients were given IFN-alpha 3 Million Units three times per week for 24 or 48 weeks and ribavirin. Sustained virological response corresponded to undetectable serum HCV RNA at treatment completion and 6 months later. Total blood lymphocyte counts and CD3(+)CD4(+), CD3(+)CD8(+), CD3(+)CD4(+)HLA-DR(+), and CD3(+)CD8(+)HLA-DR(+) lymphocyte subsets evaluated before, during, and after treatment were compared to values from 37 healthy subjects. At inclusion, patients and controls had similar total lymphocyte counts. CD3(+)CD4(+) counts and percentages were significantly higher in HCV patients. HLA-DR expression was also increased in CD4(+) (p0.0001) and CD8(+) T-cells (p = 0.0008) as compared with controls. During treatment, all lymphocyte subset counts and percentage decreased except the CD3(+)CD4(+) T-cell percentage which increased. Moreover, after 1 month of treatment, virological responders exhibited higher CD4(+) counts than nonresponders (p = 0.025), whereas they did not differ at inclusion or during the 2nd to 6th months of treatment. After treatment completion, all populations returned to baseline values. These results suggest that CD3(+)CD4(+) T-lymphocyte percentage increase under treatment could be related to IFN immunomodulation and associated with virological response.
Published: 2005

40. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal

Author: Martine, Neau-Cransac, Delphine, Morel, Pierre-Henri, Bernard, Pierre, Merville, Philippe, Revel, Luc, Potaux, and Jean, Saric
Subjects: Adult, Male, Adolescent, Calcineurin Inhibitors, Middle Aged, Mycophenolic Acid, Tacrolimus, Liver Transplantation, IMP Dehydrogenase, Creatinine, Azathioprine, Humans, Female, Renal Insufficiency, Child, Immunosuppressive Agents, Aged
Abstract: Chronic nephrotoxicity is one of the most serious side-effects of calcineurin inhibitor treatment and a factor in mortality and morbidity after liver transplantation. In our transplant centre, among patients who underwent a liver transplantation between January 1989 and December 2000, 14 liver graft recipients (6.86%) developed de novo severe renal dysfunction as defined by a serum creatinine concentration above 200 micromol/L. Renal biopsy was performed in nine cases and evidenced histological lesions compatible with chronic nephrotoxicity related to calcineurin inhibitor treatment. For nine patients, we report the results of a prospective non-randomized study consisting of cyclosporine or tacrolimus withdrawal associated with administration of mycophenolate mofetil or azathioprine. Despite this therapeutic modification, we did not observe a significant renal function improvement but on the other hand, there was no graft rejection.
Published: 2002

41. 115 PRE TRANSPLANT AFP LEVEL IS A SIMPLE AND USEFUL TEST FOR A CONTROLLED EXPANSION OF MILAN CRITERIA IN LIVER TRANSPLANT CANDIDATES FOR HEPATOCELLULAR CARCINOMA

Author: H. Badran, Daniel Cherqui, Fabrice Muscari, F. Roudot Thoraval, Fabienne Pessione, Christophe Duvoux, Armando Abergel, Thomas Decaens, S. Radenne, Martine Neau-Cransac, M.D. Gratien, Sébastien Dharancy, G.-P. Pageaux, Danielle Botta-Fridlund, A. Stacchini-Myx, Fabio Conti, Pascal Lebray, Olivier Chazouillères, Claire Francoz, Philippe Compagnon, Jean Charles Duclos-Vallée, T. Piardi, M.N. Hilleret, Ephrem Salamé, and Jérôme Dumortier
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, medicine, Milan criteria, medicine.disease, business, Gastroenterology, Test (assessment)
Published: 2010
Full Text: View/download PDF

42. Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy

Author: Martine Neau-Cransac, Karine Moreau, Jean Saric, Pierre Merville, and Colette Deminière
Subjects: Transplantation, medicine.medical_specialty, Proteinuria, Everolimus, business.industry, Urology, medicine.disease, Diabetic nephropathy, Liver transplant recipient, Sirolimus, medicine, medicine.symptom, business, medicine.drug
Published: 2008
Full Text: View/download PDF

43. Subject Index Vol. 211, 2005

Author: P. Del Giudice, Ambros Hügin, Marc Buffet, Regina Treudler, T. Rodriguez Bravo, Arash Taheri, Carolina Pellanda, Thomas J. Brill, Martine Neau-Cransac, Andreas J. Bircher, Emmanuel Molinari, Jørn Olsen, E. Gambillara, Olivier Sorg, J.-M. Pönnighaus, Christophe Antille, Paulette Bioulac-Sage, Denise Grand, Thierry André, Alexander C. Katoulis, I. Masouyé, M.A. Duchosal, Julie De Quatrebarbes, H. Zachariae, Henrik Møller, Alice Quinart, S.M. Clark, Amin Parhizgar, Giovanni Luigi Capella, Hans-Uwe Simon, Carol M. Artlett, M. Grelier, Julien Gautier, Selim Aractingi, Gürkan Kaya, Sébastien Lepreux, Julien Autier, Pierre Vabres, Mohammad Reza Fallahi, Jean-Hilaire Saurat, J.-P. Venetz, I. Schuffenecker, M. Monika Weber, Daniel Mischke, Maryam Akhyani, Günther F.L. Hofbauer, Venkata Putcha, Pierre Carraux, Farhad Handjani, Akiko Nagasaka, E. Counillon, Diamant Thaçi, Jann Lübbe, Farshad Farnaghi, Lutz Kowalzick, M. Pascual, Christian Surber, Dominique Bonneau, Dan Lipsker, Emmanuel Laffitte, Katrin Kerl, T. Kovacsovics, Roland Kaufmann, Thomas Elshorst-Schmidt, Agustin Llopis, Hassan Seirafi, Jörg Willers, Luca Borradori, Parisa Mansoori, Shinji Shimada, Heidrun Ziegler, L.A. Decosterd, N. Kunzle, Rahman Nazari, Sofia Georgala, Christine Labreze, F. Vandenbos, Jürgen Lademann, Nicolas Dupin, Behrooz Kasraee, Christos C. Zouboulis, Isabelle Daigle, P. Lesavre, Mitra Amini, Hiroyuki Matsue, Uwe Trefzer, Philippe Revel, Nicholas G. Stavrianeas, J.L. Arranz López, Karin Thoss, Jürgen Quietzsch, Sylvie De Maricourt, D.A. Fairhurst, P. Dellamonica, Renato G. Panizzon, Hans-Peter Baum, Reinhard Dummer, Ute Jacobi, Evelyne Leemans, Helen S. Evans, Maria Morales, Eva M. Valesky, Isabelle Gorin, Katharina Spanaus Schlapbach, N. Widmer, Laurence Doelker, Christian Tran, Wolfram Sterry, Aiko Miyahara, L. Garcia Martinez, Roland Blum, Silvio Hemmi, E. Elena Sorando, Jean Saric, H. Zeller, E. Laffitte, Gholamhosein R. Omrani, Mohammad Nikbakhsh, A. Carlotti, J.-H. Saurat, Naohito Hatta, and Günter Burg
Subjects: Index (economics), Statistics, Subject (documents), Dermatology, Mathematics
Published: 2005
Full Text: View/download PDF

44. EVEROLIMUS (EVL) AFTER LIVER TRANSPLANTATION (LT): A RETROSPECTIVE MULTICENTER STUDY EVALUATING MODALITIES, EFFICACY AND SAFETY OF CONVERSION TO EVL (EVEROLIVER STUDY)

Author: M. Kouassi, Monika Hurtova, Christophe Duvoux, Teresa Antonini, Jean Hardwigsen, Faouzi Saliba, Filomena Conti, O. Boillot, Yvon Calmus, Martine Neau-Cransac, Sébastien Dharancy, Jérôme Dumortier, Sylvie Radenne, and R. Lorho
Subjects: Transplantation, medicine.medical_specialty, Everolimus, Modalities, Multicenter study, business.industry, medicine.medical_treatment, medicine, Liver transplantation, business, medicine.drug, Surgery
Published: 2010
Full Text: View/download PDF

45. [35] LIVER TRANSPLANTATION (LT) FOR CHOLANGIO-CARCINOMA (CC): LONG-TERM RESULTS IN 42 PATIENTS

Author: Emmanuel Boleslawski, Philippe Wolf, S. Dharancv, Claire Vanlemmens, Philippe Mathurin, Martine Neau-Cransac, C. Meyer, Alexandre Louvet, Jean Saric, François-René Pruvot, and Anne Minello
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine.medical_treatment, Immunology, medicine, Carcinoma, Long term results, Liver transplantation, medicine.disease, business, Gastroenterology
Published: 2007
Full Text: View/download PDF

46. CO 24-Essai multicentrique national randomisé chez des malades ayant une récidive virale C post transplantation hépatique traités par peginterféron alfa-2a et ribavirine puis ribavirine seule : résultats à 18 mois de l’étude transpeg

Author: Christophe Duvoux, Karim Boudjema, L. Samelson, J. Gugenheim, François Durand, Yvon Calmus, Martine Neau-Cransac, Philippe Wolf, Sébastien Dharancy, M. Messner, Olivier Chazouillères, Y. P. Le Treut, Lionel Rostaing, Didier Samuel, Georges Philippe Pageaux, Claire Vanlemmens, and O. Boilot
Subjects: Gynecology, medicine.medical_specialty, business.industry, Gastroenterology, medicine, General Medicine, business
Published: 2006
Full Text: View/download PDF

47. 1 Multicenter randomized trial of HCV treatment with peginterferon-alpha 2a and ribavirin in liver transplant patients with established recurrent hepatitis C: Interim analysis

Author: J. Gugenheim, Lionel Rostaing, Claire Vanlemmens, Martine Neau-Cransac, François Durand, Y.P. Le Treut, Yvon Calmus, Philippe Wolf, O. Boilot, L. Samelson, M. Messner, Karim Boudjema, Christophe Duvoux, G.-P. Pageaux, Sébastien Dharancy, and Didier Samuel
Subjects: medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Peginterferon alpha-2a, Interim analysis, Gastroenterology, law.invention, chemistry.chemical_compound, chemistry, Randomized controlled trial, law, Internal medicine, Hcv treatment, Medicine, Transplant patient, Recurrent hepatitis, business
Published: 2006
Full Text: View/download PDF

48. Acknowledgement to Referees for Dermatology 2005

Author: M. Grelier, Denise Grand, Thierry André, Paulette Bioulac-Sage, Henrik Møller, Thomas J. Brill, Regina Treudler, Pierre Carraux, Sébastien Lepreux, Carol M. Artlett, Christophe Antille, I. Masouyé, Silvio Hemmi, Amin Parhizgar, Alice Quinart, Gholamhosein R. Omrani, S.M. Clark, D.A. Fairhurst, P. Del Giudice, Ambros Hügin, E. Elena Sorando, A. Carlotti, Nicholas G. Stavrianeas, Martine Neau-Cransac, P. Dellamonica, Jean Saric, Farshad Farnaghi, I. Schuffenecker, Emmanuel Laffitte, Katrin Kerl, Lutz Kowalzick, Marc Buffet, Selim Aractingi, M. Monika Weber, Julien Autier, L.A. Decosterd, Christine Labreze, J.-P. Venetz, Agustin Llopis, Aiko Miyahara, Jürgen Quietzsch, Sylvie De Maricourt, Rahman Nazari, Sofia Georgala, Nicolas Dupin, Venkata Putcha, E. Laffitte, L. Garcia Martinez, Hans-Peter Baum, Maria Morales, Hassan Seirafi, Behrooz Kasraee, Diamant Thaçi, Jann Lübbe, Luca Borradori, Christian Surber, Dominique Bonneau, Laurence Doelker, Christian Tran, E. Counillon, F. Vandenbos, Dan Lipsker, Günter Burg, Gürkan Kaya, Renato G. Panizzon, Helen S. Evans, Ute Jacobi, Evelyne Leemans, Eva M. Valesky, Mohammad Reza Fallahi, Katharina Spanaus Schlapbach, Roland Blum, Isabelle Gorin, N. Widmer, Reinhard Dummer, J.L. Arranz López, M.A. Duchosal, Karin Thoss, Wolfram Sterry, Carolina Pellanda, H. Zeller, Shinji Shimada, Emmanuel Molinari, Akiko Nagasaka, J.-M. Pönnighaus, T. Kovacsovics, Julie De Quatrebarbes, Daniel Mischke, Mohammad Nikbakhsh, Giovanni Luigi Capella, Hans-Uwe Simon, J.-H. Saurat, Julien Gautier, Naohito Hatta, Jörg Willers, Heidrun Ziegler, Günther F.L. Hofbauer, Philippe Revel, N. Kunzle, Pierre Vabres, P. Lesavre, Mitra Amini, Maryam Akhyani, Farhad Handjani, M. Pascual, Jürgen Lademann, Uwe Trefzer, Roland Kaufmann, Thomas Elshorst-Schmidt, Arash Taheri, Andreas J. Bircher, Parisa Mansoori, Jørn Olsen, Hiroyuki Matsue, E. Gambillara, Alexander C. Katoulis, Jean-Hilaire Saurat, H. Zachariae, Isabelle Daigle, T. Rodriguez Bravo, Christos C. Zouboulis, and Olivier Sorg
Subjects: Medical education, Acknowledgement, Dermatology, Psychology
Published: 2005
Full Text: View/download PDF

49. Factors associated with recurrence after transplantation for hepatocellular carcinoma

Author: K. Dharancy, Philippe Wolf, Françoise Roudot-Thoraval, Christophe Duvoux, Thomas Decaens, Jean Gugenheim, Martine Neau-Cransac, S. Hadni-Bresson, Daniel Dhumeaux, François Durand, Olivier Boillot, Daniel Cherqui, and O. Chazoullières
Subjects: Transplantation, medicine.medical_specialty, Hepatology, business.industry, Hepatocellular carcinoma, Internal medicine, medicine, medicine.disease, business, Gastroenterology
Published: 2003
Full Text: View/download PDF

50. Prediction of survival after liver transplantation (LT) for hepatocellular carcinoma (HCC) using the TNM staging classification modified for LT: Validation in a French cohort

Author: S. Hadni-Bresson, C. Meyer, G.-P. Pageaux, Sébastien Dharancy, Françoise Roudot-Thoraval, Martine Neau-Cransac, Daniel Dhumeaux, Christian Ducerf, Christophe Duvoux, Yvon Calmus, Thomas Decaens, O. Chazoullières, Daniel Cherqui, François Durand, Olivier Boillot, Jean Gugenheim, Jean Hardwigsen, and Karim Boudjema
Subjects: Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Liver transplantation, medicine.disease, Gastroenterology, TNM staging classification, Hepatocellular carcinoma, Internal medicine, Cohort, medicine, business
Published: 2003
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

57 results on '"Martine Neau"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources